55094-52-5
Chemical Structure
2,3,5-Tri-O-benzyl-D-ribono-1,4-lactone
- CAS No.: 55094-52-5
- Formula:C26H26O5
- Molecular Weight:418.49
IUPAC Name: (3R,4R,5R)-3,4-bis(benzyloxy)-5-((benzyloxy)methyl)dihydrofuran-2(3H)-one
InChIKey: LDHBSABBBAUMCZ-UBFVSLLYSA-N
SMILES: O=C1O[C@H](COCC2=CC=CC=C2)[C@@H](OCC3=CC=CC=C3)[C@H]1OCC4=CC=CC=C4
Biological Activity: 2,3,5-Tri-O-benzyl-D-ribono-1,4-lactone is a purine nucleoside analog. 2,3,5-Tri-O-benzyl-D-ribono-1,4-lactone can be synthesized from D-ribose by reacting with methanol under Fischer glycosylation conditions. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. 2,3,5-Tri-O-benzyl-D-ribono-1,4-lactone exerts anticancer activities through inhibition of DNA synthesis, induction of apoptosis, etc. 2,3,5-Tri-O-benzyl-D-ribono-1,4-lactone can be studied in anticancer research for lymphoid malignancies[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
2,3,5-Tri-O-benzyl-D-ribono-1,4-lactone | 99.97% | 2,3,5-Tri-O-benzyl-D-ribono-1,4-lactone is a purine nucleoside analog. 2,3,5-Tri-O-benzyl-D-ribono-1,4-lactone can be synthesized from D-ribose by reacting with methanol under Fischer glycosylation conditions. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. 2,3,5-Tri-O-benzyl-D-ribono-1,4-lactone exerts anticancer activities through inhibition of DNA synthesis, induction of apoptosis, etc. 2,3,5-Tri-O-benzyl-D-ribono-1,4-lactone can be studied in anticancer research for lymphoid malignancies. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18(23):3373-88. [Content Brief]
- [2]. Mallikharjuna Rao Lambu et al., Synthesis of C-spiro-glycoconjugates from sugar lactones via zinc mediated Barbier reaction. RSC Adv., 2014, 4, 11023-11028.
